Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2007-05-16
2011-11-15
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S679000, C514S456000
Reexamination Certificate
active
08058314
ABSTRACT:
This invention provides the methodology and agents for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide for the release of normally retained proteins from the endoplasmic reticulum. The present invention is particularly useful for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention or degradation of mis-assembled or mis-folded proteins.
REFERENCES:
patent: 4866072 (1989-09-01), Edwards et al.
patent: 5364762 (1994-11-01), Dornmair et al.
patent: 5384128 (1995-01-01), Meezan et al.
patent: 5401777 (1995-03-01), Ammon et al.
patent: 5434086 (1995-07-01), Collins et al.
patent: 5602110 (1997-02-01), Drumm et al.
patent: 5639458 (1997-06-01), Olsson et al.
patent: 5670626 (1997-09-01), Chang
patent: 5674898 (1997-10-01), Cheng et al.
patent: 5679864 (1997-10-01), Krackov et al.
patent: 5707855 (1998-01-01), Hancock et al.
patent: 5733720 (1998-03-01), Olivo
patent: 5734023 (1998-03-01), Nag et al.
patent: 5750571 (1998-05-01), Cheng et al.
patent: 5763263 (1998-06-01), Dehlinger
patent: 5834421 (1998-11-01), Cheng et al.
patent: 5846998 (1998-12-01), Schieven
patent: 5861259 (1999-01-01), Roberts et al.
patent: 5861415 (1999-01-01), Majeed et al.
patent: 5866319 (1999-02-01), Alizon et al.
patent: 5869264 (1999-02-01), Horisberger et al.
patent: 5877210 (1999-03-01), Schieven
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5891924 (1999-04-01), Aggarwal
patent: 5912176 (1999-06-01), Wang
patent: 5939536 (1999-08-01), O'Riordan et al.
patent: 5942493 (1999-08-01), Kutscher et al.
patent: 5981714 (1999-11-01), Cheng et al.
patent: 5985824 (1999-11-01), Cheng et al.
patent: 6015828 (2000-01-01), Cuppoletti
patent: 6093567 (2000-07-01), Gregory et al.
patent: 6270747 (2001-08-01), Nadel et al.
patent: 6323191 (2001-11-01), Harris et al.
patent: 6344475 (2002-02-01), Caplan et al.
patent: 6566324 (2003-05-01), Nadel et al.
patent: 6664272 (2003-12-01), Snyder et al.
patent: 6673843 (2004-01-01), Arbiser
patent: 2001/0004117 (2001-06-01), Chikamatsu et al.
patent: 2001/0036919 (2001-11-01), Nadel et al.
patent: 2002/0019382 (2002-02-01), Snyder et al.
patent: 09/028392 (1997-02-01), None
patent: WO 93/13768 (1993-07-01), None
patent: WO 94/04139 (1994-03-01), None
patent: WO 95/05810 (1995-03-01), None
patent: WO 95/07933 (1995-03-01), None
patent: WO 95/12420 (1995-05-01), None
patent: WO 96/32139 (1996-10-01), None
patent: WO 98/37878 (1998-09-01), None
patent: WO 00/24391 (2000-05-01), None
patent: WO 00/70949 (2000-11-01), None
patent: WO 01/40188 (2001-06-01), None
patent: WO 02/02582 (2002-01-01), None
patent: WO 03/007975 (2003-01-01), None
patent: WO 03/035007 (2003-05-01), None
patent: WO 03/049717 (2003-06-01), None
Intelihealth (Nov. 2008) by NHLBI, 3 pages.
Phillips http://cysticfibrosis.respironics.com/treatment.asp (2010) 4 pages.
Welsh et al. Scientific American (1995), 1-9.
Hardie et al “Immunolocalization of Transforming Growth α Factor and Epidermal Growth Factor Receptor in Lungs of Patients with Cystic Fibrosis” Pediatric and Developmental Pathology 2, 415-423, 1999.
Rubin, Bruce K. “Mucus, Phlegm, and Sputum in Cystic Fibrosis” Respiratory Care, vol. 54, No. 6, 726-32, Jun. 2009.
Amara, et al., “Intracellular Protein Trafficking Defects in Human Disease”, Trends in Cell Biology, 2: 145-149, 1992.
Ammon, et al., “Pharmacology ofCurcuma longa” Planta Med. 57:1-7, 1991.
Araanjo, et al., “Potentiation by Turmeric and Curcumin of Gamma-Radiation-Induced Chromosome Aberrations in Chinese Hamster Ovary Cells”, Teratog. Carcinog. Mutagen., 19(1):9-18, 1999.
Aranjo, et al., “Biological Activities ofCurcuma longa L.” Mem. Inst. Oswaldo Cruz. 96: 723-728, 2001.
Asai, et al., Occurrence of Orally Administered Curcuminoid as Glucuronide and Glucuronide/Sulfate Conjugates in Rat Plasma, Life Sciences, 67:2785-2793, 2000.
Bargon, et al., “Down-Regulation of Cystic Fibrosis Transmembrane Conductance Regulator Gene Expression by Agents that Modulate Intracellular Divalent Cations”, Modular and Cellular Biology, 12(4): 1872-1878, 1992.
Barmatz, et al., “The Structure, Function, and Cellular Regulation of Ryanodine-Sensitive Ca2+ Release Channels”, Int Rev Cytol. 183: 185-270, 1998.
Basavappa et al., “Cl- and K+ Transport in Human Biliary Cell Lines”, Gastroenterology, 104(6): 1796-1805, 1993.
Beavo, et al., “Primary Sequence of Cyclic Nucleotide Phosphodiesterase Isozymes and the Design of Selective Inhibitors” Trends Pharmacol Sciences, 11:150, 1990.
Bell, et al., “T84 Cells: Anion Selectivity Demonstrates Expression of Cl” Conductance Affected in Cystic Fibrosis, Am. J. Physiol. 262: C555-0562, 1992.
Berridge, “The Biology and Medine of Calcium Signalling”, Mol. Cell. Endocrin, 98: 119-124, 1994.
Berridge, M.J., “Inositol Trisphosphate and Calcium Signalling”, Nature, 361: 315-325, 1993.
Beutler, et al., “Mutation Analysis in Hereditary Hemochromatosis”, Blood Cells MoL Dis., 22: 187-194, 1996.
Bhavanishankar, et al., “Toxicity Studies on Turmeric -Long Term Toxicity Studies in Albino Rats and Monkeys”, Journal of Food Science and Technology, India. 23(5):287-290, 1986.
Bhavanishankar, et al., Reproductive Response of Rats Fed Turmeric and its Alcoholic Extract, Journal of Food Science and Technology, India. 24(1): 45-49, 1987.
Bille, et al., “Subchronic Oral Toxicity of Turmeric Oleoresin in Pigs”, Food Chem. Toxicol. 23(11): 967-973, 1985.
Bilmen, et al., “Inhibition of the SERCA Ca2+ Pumps by Curcumin. Curcumin Putatively Stabilizes the Interaction Between the Nucleotide-Binding and Phosphorylation Domains in the Absence of ATP”, Eur. J. Biochem., 268:6318-6327, 2001.
Boucher, “What Can We Expect for Cystic Fibrosis”, Drugs, 43(4): 431-439, 1992.
Brenan, et al., Automated Fluorometric Assay for T Cell Cytotoxicity,J. Immuno. Methods, 112: 121-131, 1988.
Brennan, et al., “Cystic Fibrosis”, Cur Opin Infect Dis., 15(2): 175-182, 2002.
Brihaye, et al., “Chronic Rhinosinusitis in Cystic Fibrosis (Mucoviscidosis)”, Acta Oto-Rhino Laryngologica Belg., 51: 323-337, 1997.
Canny et al., “The calcium pump inhibitors thapsigargin and curcumin alter delta F508 CFTR-chaperone interactions.” (2003) FASEB J. 17(4-5).
Chao, et al., “Calcium-and CaMKII- Dependent Chloride Secretion Induced by the Microsomal Ca2+ATPase Inhibitor 2,5-Di-(Tert-Buty1)-1,4-Hydroquinone in Cystic Fibrosis Pancreatic Epithelial Cells”, J. Clin. Invest. 96:1794-1801, 1995.
Cheek, T.R. “Calcium Regulation and Homeostasis”, Curr. Opin. Cell. Biol. 3: 199-205, 1991.
Chen, et al., “Induction of HSP70 Gene Expression by Modulation of Ca+2 Ion and Cellular p53 Protein by Curcumin in Colorectal Carcinoma Cells”, Molecular Carcinogenesis, 17: 224-234, 1996.
Cheng, et al., “Defective Intracellular Transport and Processing of CFTR is the Molecular Basis of Most Cystic Fibrosis”, Cell, 63:827-834, 1990.
Cheng, et al., “Phase 1 Clinical Trial of Curcumm, A Chemopreventive Agent”, in Patients with High-Risk of Pre-Malignant Lesions, Anticancer Research, 21: 2895-2900, 2001.
Chillaron, et al., “An Intracellular Trafficking Defect in Type 1 Cystinuria rBAT Mutants M46T and 467K”, 1 Biol. Chem. 272(14): 9543-9549, 1997.
Choudhury, et al., “Intracellular Association Between UDP-Glucose: Glycoprotein Glucosyltransferase and an Incompletely Folded Variant of ai-Antitrypsin”, The Journal of Biological Chemistry, 272(20): 13446-13451, 1997.
Christensen, et al., “Derivatives of Thapsigargin as Probes of its Binding Site on Endoplasmic Reticulum Ca2+ ATPase”, Federation of European Biochemical Societies, 335(3): 34
Caplan Michael J.
Egan Marie E.
Choate Hall & Stewart LLP
Fetterolf Brandon
Gembeh Shirley V
Yale University
LandOfFree
Conductance of improperly folded proteins through the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conductance of improperly folded proteins through the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conductance of improperly folded proteins through the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286447